Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis-Reference-Cited by-同舟云学术

Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis

Published:2021-04-07 Issue:2 Volume:10 Page:911-923
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Wu Hailan,Wang Zhiqiang,Wang Yu,Yu Jicheng,Fan Yaxin,Li Yi,Wang Jingjing,Cao Guoying,Guo Beining,Chen Yuancheng,Liu Xiaofen,Bian Xingchen,Wu Jufang,Li Hongtao,Wu Xiaojie,Zhang Jing^ORCID

Funder

New Drug Creation and Manufacturing Programme of the Ministry of Science and Technology of China

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-021-00428-4.pdf

Reference17 articles.

1. Sun JH, Wang ZQ, Gu XL, Mu R. Comparative study of L-and D-ornidazole in terms of central nervous system toxicity in mice. J Chin Pharm Univ. 2008;4:343–7.

2. Hu J, Zhang J, Wu S, et al. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria. Int J Antimicrob Agents. 2014;44:514–9.

3. Hu J, Zhang J, Chen Y, et al. In vitro bactericidal property of levornidazole against Bacteroides fragilis studied by time-kill assay and sigmoid Emax model analysis. Int J Antimicrob Agents. 2015;45:673–5.

4. Guo B, He G, Wu X, et al. Clinical pharmacokinetics of levornidazole in elderly subjects and dosing regimen evaluation using pharmacokinetic/pharmacodynamic analysis. Clin Ther. 2017;39:1336–46.

5. Wu H, Xie S, Yu J, et al. Pharmacokinetics and pharmacodynamics of levornidazole in patients with intra-abdominal anaerobic infection. Clin Ther. 2018;40:1548–55.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis;International Journal of Antimicrobial Agents;2023-04